21606-04-2

Basic information

• Product Name: 1-Methyl-3-nitrophthalate
• Synonyms: 1-Methyl-3-nitrophthalate;3-Nitro-1,2-Benzenedi-Carboxylic Acid Monomethyl Ester;3-Nitro-1,2-benzenedicarboxylic acid 1-methyl ester;METHYL2-CARBOXY-3-NITROBENZOATE;Methyl 3-nitro-2-carboxyl benzoate;3-Nitro-phthalic acid 1-Methyl ester;2-(Methoxycarbonyl)-6-nitrobenzoic acid;2-Methoxyxcarbonyl-6-nitrobenzoic acid
• CAS NO: 21606-04-2
• Molecular Formula: C₉H₇NO₆
• Molecular Weight: 225.16
• Mol File: 21606-04-2.mol
• Article Data: 10

Chemical Properties

• Melting Point: 160.0 to 164.0 °C
• Boiling Point: 409.199 °C at 760 mmHg
• Flash Point: 201.277 °C
• Appearance: /
• Density: 1.484 g/cm³
• Vapor Pressure: 1.98E-07mmHg at 25°C
• Refractive Index: 1.594
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.87±0.30(Predicted)
• CAS DataBase Reference: 1-Methyl-3-nitrophthalate(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-3-nitrophthalate(21606-04-2)
• EPA Substance Registry System: 1-Methyl-3-nitrophthalate(21606-04-2)

Safety Data

• Hazardous Substances Data: 21606-04-2(Hazardous Substances Data)

Usage

Chemical Properties

light yellow crystalline powder

Uses

Methyl 3-Nitrophthalate is an intermediate in the synthesis of (αS)-3-Ethoxy-4-methoxy-α-[(methylsulfonyl)methyl]-N-[(1S)-1-phenylethyl]-benzenemethanamine which is an impurity of Apremilast (A729700), which is an oral phosphodiesterase 4 inhibitor used for treating psoriatic arthritis.

InChI:InChI=1/C9H7NO6/c1-16-9(13)5-3-2-4-6(10(14)15)7(5)8(11)12/h2-4H,1H3,(H,11,12)

Upstream product

• 67-56-1 methanol 
• 603-11-2 3-nitrophthalic acid 
• 641-70-3 3-nitrophthalic acid anhydride 
• 124-41-4 sodium methylate 
• 13365-26-9 dimethyl 3-nitrophthalate 
• 7719-09-7 thionyl chloride 
• 6744-85-0 2-(methoxycarbonyl)-3-nitrobenzoic acid 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 151094-78-9 6-nitro-2-carbomethoxyphenyl isocyanate 
• 6744-85-0 2-(methoxycarbonyl)-3-nitrobenzoic acid 
• 856414-36-3 2-Azidocarbonyl-3-nitro-benzoic acid methyl ester 
• 459146-51-1 8-nitro-3-phenylquinazoline-2,4-(1H,3H)-dione 
• 459146-64-6 8-amino-3-(4-methoxyphenyl)quinazoline-2,4-(1H,3H)-dione 
• 459146-52-2 3-(4-methoxyphenyl)-8-nitroquinazoline-2,4-(1H,3H)-dione 
• 459146-65-7 5-phenyl-4H-imidazo[4,5,1-ij]quinazoline-2,4,6(1H,5H)-thione 
• 459146-66-8 5-(4-methoxyphenyl)-4H-imidazo[4,5,1-ij]quinazoline-2,4,6(1H,5H)-thione 
• 459146-50-0 N-[8-nitro-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl]benzamide 
• 145040-37-5 candesartan cilexetil 
• 139481-72-4 2-Ethoxy-1-[[2'-(N-triphenylmethyltetrazol-5-yl)-biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid 
• 150058-27-8 2-ethoxy-1H-benzimidazole-7-carboxylic acid methyl ester 
• 57113-91-4 methyl 3-nitroanthranilate 
• 107582-20-7 2,3-diaminobenzoic acid methyl ester 

Relevant articles and documents

Preparation method of lenalidomide

The invention discloses a synthesizing method of lenalidomide. The method comprises the steps that the compound shown in the formula 1 is reacted with thionyl chloride and an alcohol solvent to obtainthe compound shown in the formula 2; the compound shown in the formula 2 is reacted with chloroformate to obtain anhydride, the anhydride is reduced to obtain the compound shown in the formula 3; thecompound shown in the formula 3 is reacted with a chloride agent to obtain the compound shown in the formula 4; the compound shown in the formula 4 and the compound shown in the formula 5 are subjected to a condensation reaction, and the compound shown in the formula 6 is obtained; the compound shown in the formula 6 is reduced in the presence of hydrogen to obtain the lenalidomide shown in the formula 7. The initial raw materials used in the method are low in cost and easy to obtain, the synthesizing steps are simple, the operation is simple, the yield is high, the production cost is low, and industrial production is facilitated.

PROCESS FOR PREPARATION OF CANDESART AN CILEXETIL SUBSTANTIALLY FREE OF DES-CANDESARTAN CILEXETIL IMPURITY

The present invention provides a process for preparation of candeartan cilexetil substantially free of 2,3-dihydro-2-oxo-3-[[2'-(2H-tetrazol-5-yl)[l,l-biphenyl]-4- yl]methyl]-l-[[(cyclohexyloxy)carbonyl]oxy]ethylester-lH-benzimidazole-7- carboxylate (des-candesartan cilexetil) impurity.

PROCESS FOR PREPARING CANDESARTAN CILEXETIL

A process for preparing candesartan cilexetil.